19:00 , May 4, 2018 |  BC Week In Review  |  Financial News

Alzheimer's company Alzheon postpones IPO

Alzheon Inc. (Framingham, Mass.) has postponed its IPO, according to a statement to BioCentury. In March, the Alzheimer's disease company had filed for a listing on NASDAQ underwritten by Citigroup, Piper Jaffray, Canaccord Genuity and...
20:55 , Apr 30, 2018 |  BC Extra  |  Financial News

Alzheon postpones NASDAQ IPO

Alzheon Inc. (Framingham, Mass.) has postponed its IPO, according to a statement to BioCentury. In March, the Alzheimer's disease company had filed for a listing on NASDAQ underwritten by Citigroup, Piper Jaffray, Canaccord Genuity and...
17:31 , Mar 23, 2018 |  BC Week In Review  |  Financial News

Alzheon proposes IPO

Alzheon Inc. (Framingham, Mass.) proposed to raise up to $80.5 million on March 16 in an IPO on NASDAQ underwritten by Citigroup, Piper Jaffray, Canaccord Genuity and JMP Securities. Alzheon plans to start a Phase...
19:24 , Mar 19, 2018 |  BC Extra  |  Financial News

Alzheimer's play Alzheon files for IPO

Alzheon Inc. (Framingham, Mass.) filed to raise up to $80.5 million in an IPO on NASDAQ underwritten by Citigroup, Piper Jaffray, Canaccord Genuity and JMP Securities. Alzheon plans to start a Phase III trial this...
21:36 , Dec 15, 2017 |  BC Week In Review  |  Financial News

Bellus Health raises C$20M in follow-on

On Dec. 12, Bellus Health Inc. (TSX:BLU) raised C$20 million ($15.6 million) through the sale of 52.6 million shares at C$0.38 in a follow-on. The price values the company at C$45.4 million ($35.4 million). Bloom...
21:41 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Alzheon reports Phase I bridging dose analysis data for AD candidate ALZ-801

Based on a bridging dose analysis of 3 placebo-controlled Phase I trials evaluating the safety and pharmacokinetics of various dosing regimens and formulations of Alzheimer’s disease candidate ALZ-801 in 127 healthy volunteers, Alzheon Inc. (Framingham,...
07:00 , Aug 15, 2016 |  BioCentury  |  Finance

Serving returns

China's Ally Bridge Group hit the investment world's radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that...
07:00 , Mar 14, 2016 |  BioCentury  |  Emerging Company Profile

AMO's CNS ammunition

AMO Pharma Ltd. is in-licensing therapies for rare genetic diseases with no treatment options, starting with two potentially disease-modifying candidates for fragile X syndrome and myotonic dystrophy type 1. The company's first candidate is AMO-01...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

ALZ-801: Additional Phase III data

Pooled data from a subgroup of 252 mild to moderate AD patients homozygous for apolipoprotein E epsilon 4 ( APOE4 ) in a North American Phase III trial and a European Phase III trial showed...
01:38 , Nov 7, 2015 |  BC Extra  |  Clinical News

Alzheon: Data justify pursuit of homozygous AD patients

Alzheon Inc. (Framingham, Mass.) said tramiprosate improved cognition in mild to moderate Alzheimer's disease patients homozygous for apolipoprotein E epsilon 4 ( APOE4 ) in a subgroup analysis of two earlier Phase III studies. Alzheon...